Health Care • Biotechnology: Pharmaceutical Preparations
$0.29 ▼ -0.01
(-4.69%)
MKT CAP: $55.9M • VOL: 1.02M
52W L $0 52W H $2
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
HRTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $154.9M | $144.3M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $113.6M | $105.6M | — |
| Gross Margin % | 73.3% | 73.2% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$2.5M | -$11.5M | -$110.6M |
| Operating Margin % | -1.6% | -8.0% | — |
| Net Income (GAAP) | -$20.0M | -$14.0M | -$111.0M |
| EBITDA (Normalized) | -$2.3M | -$10.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$27.6M | -$22.5M | -$58.8M |
| Capital Expenditures (CapEx) | $317.0K | $1.7M | — |
| Free Cash Flow (FCF) | -$27.9M | -$24.2M | -$58.8M |
| FCF Margin % | -18.0% | -16.8% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $28.6M | $25.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $14.3M | -$33.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HRTX.